PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• M. V. Mateos,
• N. Bahlis,
• L. Costa,
• A. Perrot,
• L. Pei,
• M. Rubin,
• K. Lantz,
• W. Sun,
• M. Jaffe,
• R. Kobos,
• A. Nooka

Affiliations

M. V. Mateos

1 Hospital Clínico Universitario de Salamanca, Salamanca, Spain

N. Bahlis

2 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada

L. Costa

3 University of Alabama at Birmingham, Birmingham, United States of America

A. Perrot

4 Centre Hospitalier Universitaire de Toulouse, Service d’Hématologie, Toulouse, France

L. Pei

5 Janssen Research & Development, Raritan

M. Rubin

6 Janssen Research & Development, Spring House

K. Lantz

6 Janssen Research & Development, Spring House

W. Sun

7 Janssen Research & Development, Los Angeles

M. Jaffe

5 Janssen Research & Development, Raritan

R. Kobos

5 Janssen Research & Development, Raritan

A. Nooka

8 Winship Cancer Institute, Emory University, Atlanta, United States of America